As we move into the new year, we are excited to share a significant milestone in SCI research, that has been directly funded by your donations. The CSRO was proud to fund the Up-LIFT trial in Toronto as Onward’s research network and play a part in the announcement of this groundbreaking new research.
Onward’s Research Announcement:
After more than a decade of dedicated research, the ARC-EX® System received FDA De Novo classification and authorization to market the system, the world’s first non-invasive spinal cord stimulation system proven to improve strength and sensation after chronic SCI.
Here are some key highlights of the ARC-EX System:
⭐️ 90% of clinical trial participants showed improved strength or function* in clinical trials
⭐️ Benefits seen up to 34 years post-injury* in clinical trials
⭐️ Named a Time Magazine Best Invention of 2024
For the first time there is an approved therapy to improve hand strength and sensation for people with SCI – including individuals with chronic spinal cord injuries. This recognition is particularly meaningful because it acknowledges more than just technological innovation – it validates the benefits of this therapy for the millions of people worldwide who dream of regaining movement and independence after SCI.
In the clinical trials, patients demonstrated significant improvements, even decades after their injuries, reinforcing the therapy’s long-term potential. This is a validation of the years of hard work and research that have gone into developing this solution.
As we look forward to the year ahead, we are excited about the possibilities that this new treatment opens up and remain committed to advancing SCI therapies to enhance quality of life for those living with chronic, non-progressive neurological deficits.
We also want to remind you that the ARC-EX System is intended for use with functional task practice in a clinical setting to improve hand strength and sensation in individuals aged 18-75 with chronic, non-progressive SCI (C2-C8). Please note that all other ONWARD Medical devices and therapies, including ARC-IM®, ARC-BCI®, and ARC Therapy™ with brain-computer interfaces (BCIs), remain investigational and are not yet commercially approved. Outcomes vary, and patient experiences should be reviewed in the context of full clinical study data.
Thank you for your continued partnership and teamwork in reaching this critical milestone. We are excited about the road ahead and look forward to achieving even more together in service to the spinal cord injury community.
This research was made possible by a dedicated community who shares our vision, and allowed us to fund the trials of this groundbreaking technology in Toronto. Thank you for being with us on the journey to a cure for paralysis caused by spinal cord injury.